Trial Profile
A European Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Enzalutamide Treatment in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Mar 2022
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PREMISE
- Sponsors Astellas Pharma Europe Ltd
- 01 Mar 2022 Results published in the International Journal of Cancer
- 26 Jul 2020 Results assessing pain outcomes in patients with metastatic castration-resistant prostate cancer presented at the 35th Congress of the European Association of Urology
- 26 Jul 2020 Results presented at the 35th Congress of the European Association of Urology